Technical Analysis for PDSB - PDS Biotechnology Corporation

Grade Last Price % Change Price Change
grade F 5.71 6.13% 0.33
PDSB closed up 6.13 percent on Thursday, September 19, 2019, on 2.06 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical PDSB trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
New Uptrend Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup 6.13%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.13%
Pocket Pivot Bullish Swing Setup 6.13%
Oversold Stochastic Weakness 6.13%
Oversold Stochastic Weakness 13.07%

Older signals for PDSB ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.
Medicine Cancer Clinical Medicine Oncology Immunotherapy Cancers Prostate Cancer Breast Cancer Cancer Immunotherapy Melanoma Immunotherapies Head And Neck Cancer Oncolytics Biotech Cervical Cancer Anal Cancer Breast Cancers Northwest Biotherapeutics Treatment Of Melanoma
Is PDSB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 23.6
52 Week Low 5.0
Average Volume 12,788
200-Day Moving Average 7.1293
50-Day Moving Average 5.9426
20-Day Moving Average 5.4433
10-Day Moving Average 5.2535
Average True Range 0.3234
ADX 37.61
+DI 19.6677
-DI 16.5927
Chandelier Exit (Long, 3 ATRs ) 5.4698
Chandelier Exit (Short, 3 ATRs ) 5.9702
Upper Bollinger Band 5.9855
Lower Bollinger Band 4.9011
Percent B (%b) 0.75
BandWidth 19.921739
MACD Line -0.2019
MACD Signal Line -0.2385
MACD Histogram 0.0366
Fundamentals Value
Market Cap 176.16 Million
Num Shares 30.9 Million
EPS -1.57
Price-to-Earnings (P/E) Ratio -3.64
Price-to-Sales 0.00
Price-to-Book 3.94
PEG Ratio -0.07
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.65
Resistance 3 (R3) 6.62 6.28 6.50
Resistance 2 (R2) 6.28 6.04 6.30 6.44
Resistance 1 (R1) 6.00 5.89 6.14 6.02 6.39
Pivot Point 5.65 5.65 5.72 5.67 5.65
Support 1 (S1) 5.37 5.41 5.51 5.40 5.03
Support 2 (S2) 5.02 5.26 5.04 4.98
Support 3 (S3) 4.74 5.02 4.92
Support 4 (S4) 4.77